Differential response to DSS colitis and IFX in WT and octn1^-/- mice. Panels A and B: Four-point disease activity index (DAI) and body weight loss represented separately as percentage of day 1, over the entire treatment period. Traces and symbols corresponding to the eight treatment groups are indicated. Values are mean ± SD of 4 mice (per group). Panel C: Rachmilewitz and Geboes score (see Methods section) in WT and octn1^-/- treated mice. Data are represented of at least 3 independent experiments. Panel D: 20X Representative figures of colon (hematoxylin and eosin) in WT mice (upper panels) and in octn1^-/- mice (lower panels) with no treatment, DSS or treated by IFX. Panel E: Representative images of multiplex immunofluorescence staining. The panel displays multiplex IHC 8 images after spectral unmixing, of LY6G + neutrophils (green), CD8 + cytotoxic T cells (orange), CD4 + T helper cells (yellow), CD11b + granulocytes (red), and a nuclear marker (DAPI, blue). Scale bars, 50 μm. Panel F: Serum concentration of IFX in healthy and DSS-treated WT and octn1^-/- mice. Blood samples were collected at sacrifice. Infliximab was quantified by ELISA (Sanquin, the Netherlands) according to the manufacturer’s recommendations. Values are mean ± SD of 4 mice (per group).